Risk of corrected QT interval prolongation after pamidronate infusion in children

J Clin Endocrinol Metab. 2010 Aug;95(8):3768-70. doi: 10.1210/jc.2009-2814. Epub 2010 May 25.

Abstract

Background: Hypocalcemia carries a risk of cardiac conduction incidents and death. Hypocalcemia is a frequent adverse effect of pamidronate.

Objective: The objective of this study was to investigate whether pamidronate infusion lengthens the ventricular repolarization in children.

Design and methods: Thirty-four children with cerebral palsy and severe osteoporosis were treated for approximately 1 yr with pamidronate (three times per year). Calcemia and corrected QT interval (QTc) (in which the QT interval is a measure between the Q and T waves in the electrical cycle of the heart) were measured before and after each cycle of intravenous infusions.

Results: Pamidronate decreased calcemia in all patients from 2.40 to 2.21 mm (P<0.0001) and increased QTc from 390 to 403 ms (P<0.0001), with 7.4% of postinfusion QTc becoming longer than 440 ms. QTc at baseline was significantly correlated to final QTc (P<0.0001; r2=0.27).

Conclusions: Because we observed a lengthening in QTc after bisphosphonate infusion, we recommend that children treated with pamidronate should receive attention as to other possible risk factors of prolonged QT and have a preinfusion and postinfusion measurement of their QTc.

MeSH terms

  • Adolescent
  • Arrhythmias, Cardiac / chemically induced*
  • Arrhythmias, Cardiac / physiopathology
  • Cerebral Palsy / drug therapy*
  • Child
  • Diphosphonates / adverse effects*
  • Diphosphonates / therapeutic use
  • Electrocardiography
  • Female
  • Heart Conduction System / drug effects*
  • Heart Conduction System / physiopathology
  • Humans
  • Male
  • Osteoporosis / drug therapy*
  • Pamidronate
  • Risk Factors

Substances

  • Diphosphonates
  • Pamidronate